Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Akorn AKRXQ

Healthcare Drug Manufacturers - Major
Akorn Inc is a pharmaceutical company. It is engaged in the development, manufacturing, and marketing of generic and prescription pharmaceuticals. The firm has two segments namely Prescription Pharmaceuticals and Consumer Health. The Prescription Pharmaceuticals segment consists of generic and branded prescription pharmaceuticals including sterile ophthalmics, injectables, and inhalants, and... see more

Recent & Breaking News (OTCPK:AKRXQ)

Wall Street's M&A Chatter From April 18: Akorn, Cardinal Health, Post-Weetabix, Nivalis Therapeutics-Alpine Immune

Benzinga.com  April 19, 2017

Analyst: Akorn Could Be Sold For As Much As $34 Per Share, But There's Double-Digits Downside If Deal Doesn't Happen

Benzinga.com  April 11, 2017

The Market In 5 Minutes

Benzinga.com  April 10, 2017

16 Stocks Moving In Monday's Pre-Market Session

Benzinga.com  April 10, 2017

6 Stocks To Watch For April 10, 2017

Benzinga.com  April 10, 2017

Akorn Confirms Discussions with Fresenius Kabi

GlobeNewswire April 7, 2017

Generic Drugs Stocks on Investors' Radar -- Zoetis, Mallinckrodt, Akorn, and MYOS RENS Technology

PR Newswire April 4, 2017

Does Reward Potential Still Outweigh The Risk In Akorn Shares?

Benzinga.com  March 6, 2017

15 Biggest Mid-Day Losers For Monday

Benzinga.com  March 6, 2017

Akorn Receives FDA Approval for Ephedrine Sulfate Injection, USP

GlobeNewswire March 2, 2017

Akorn Provides Fourth Quarter and Full Year 2016 Results and Outlines Full Year 2017 Guidance

GlobeNewswire March 1, 2017

Akorn Receives Approval for Mycophenolate Mofetil for Injection, USP

GlobeNewswire February 28, 2017

Technical Reports on Generic Drugs Stocks -- Zoetis, Mallinckrodt, Akorn, and MYOS RENS Technology

PR Newswire February 27, 2017

Akorn to Report Fourth Quarter and Full Year 2016 Results

GlobeNewswire February 6, 2017

Watch These 10 Huge Put Purchases In Tuesday Trade

Benzinga.com  January 31, 2017

Technical Reports on Generic Drugs Stocks -- Zoetis, Mallinckrodt, Akorn, and Diplomat Pharmacy

PR Newswire January 24, 2017

Akorn to Present at 35th Annual J.P Morgan Healthcare Conference

GlobeNewswire December 21, 2016

Biotech Companies Continue Quest for Advanced Drug Developments

PR Newswire December 13, 2016

Benzinga's Volume Movers

Benzinga.com  December 12, 2016

Research Reports Initiation on Healthcare Stocks -- Valeant Pharma, Akorn, Universal Health Services, and LifePoint Health

PR Newswire December 5, 2016